Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Mitochondria and lipid defects in hereditary progranulin-related frontotemporal dementia

  • Ondaro, Jon
  • Zúñiga Elizari, Jose Luis
  • Zufiría García, Mónica
  • Garciandia-Arcelus, Maddi
  • Sánchez Molleda, Ángela
  • Zulaica Ijurco, Miren
  • Lafarga, Miguel
  • Riancho, Javier
  • López de Munain, Adolfo
  • Moreno, Fermin
  • Gil Bea, Francisco Javier
  • Gerenu, Gorka
Frontotemporal dementia (FTD) is a neurodegenerative disorder predominantly affecting individuals under 65 years of age, characterized by significant behavioral and language disabilities. Despite extensive research efforts, effective treatments for FTD remain elusive. Familial cases of FTD have been linked to genetic mutations in several key genes, among these, mutations in granulin (GRN) account for 5–20% of cases, leading to haploinsufficiency of progranulin (PGRN), a multifunctional glycoprotein. This study investigates the cellular pathology associated with GRN insufficiency by using fibroblasts derived from FTD patients carrying the c.709-1G>A GRN mutation (FTD-GRN). These fibroblasts exhibited pathological hallmarks of FTD, including lysosomes, autophagosomes, and lipofuscin accumulation, mirroring observations in affected patient tissues. Notably, we report mitochondrial abnormalities, characterized by mitochondrial swelling which is associated with decreased mitochondrial respiration, and lipid droplet accumulation, reflecting altered lipid metabolism. Experimental supplementation with recombinant human progranulin (rhPGRN) was associated with recovery of lysosomal acidification and attenuation of mitochondrial and lipid abnormalities in vitro. This study reveals that GRN haploinsufficiency induces mitochondrial and lipid dysfunctions, suggesting that these pathways may contribute to FTD-GRN pathogenesis and could be of interest for therapeutic development., This research was funded by Grant PID2023-153029OA-I00 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by 'ERDF A way of making Europe', by 'ERDF/EU', by the 'European Union' or by the 'European Union NextGenerationEU/PRTR'. The Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union through the European Regional Development Fund (ERDF) (grant numbers P18/01066, PI19/01637, PI21/00153, PI24/01025); by CIBERNED-Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (grant number CB06/05/1126, Group 609); by the Diputación Foral de Gipuzkoa (project 2021-CIEN-000020-01); by EiTB Maratoia (BIO17/ND/023/BD); by Fundació La Marató (grant number 202006-32); and by the IKUR strategy of the Basque Government (NEURODEGENPROT project), as well as the Basque Government Department of Health (Eusko Jaurlaritzako Osasun Saila; grant numbers 2017222027, 2018111042, 2019222020, and 2021333050). J.O., J.L., M.Z., and M.G. received predoctoral support from the Department of Education of the Basque Government through grants PRE2018_1_0095, PRE2022_1_0315, PRE2015_1_0023, and PRE2020_1_0122, respectively. F.G. was supported by the Roche 'Stop Fuga de Cerebros' program (BIO19/ROCHE/017/BD). G.G. was funded by the Juan de la Cierva-Incorporación fellowship from the Spanish Ministry of Science and Innovation (IJC2019-039965-I). F.G., and G.G. received additional support from the IKERBASQUE Research Foundation. The APC was funded by the same funding sources, in accordance with the authors' affiliation with the University of the Basque Country (UPV/EHU).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis

  • Zufiría García, Mónica
  • Pikatza-Menoio, Oihane
  • Garciandia-Arcelus, Maddi
  • Bengoetxea, Xabier
  • Jiménez Zúñiga, Andrés
  • Elicegui, Amaia
  • Levchuk, María
  • Arnold-García, Olatz
  • Ondaro, Jon
  • Iruzubieta, Pablo
  • Rodríguez-Gómez, Laura
  • Fernández-Pelayo, Uxoa
  • Muñoz-Oreja, Mikel
  • Aiastui, Ana
  • García-Verdugo, José Manuel
  • Herranz-Pérez, Vicente
  • Zulaica Ijurco, Miren
  • Poza, Juan José
  • Ruiz Onandi, Rebeca
  • Fernández-Torrón, Roberto
  • Espinal, Juan Bautista
  • Bonilla, Mario
  • Lersundi, Ana
  • Fernández-Eulate, Gorka
  • Riancho, Javier
  • Vallejo-Illarramendi, Ainara
  • Holt, Ian James
  • Sáenz, Amets
  • Malfatti, Edoardo
  • Duguez, Stéphanie
  • Blázquez, Lorea
  • López de Munain, Adolfo
  • Gerenu, Gorka
  • Gil Bea, Francisco Javier
  • Alonso-Martín, Sonia
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS. We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS-silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue., This research was supported by the Biodonostia Health Research Institute (Biodonostia HRI) and CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/05/1126, Group 609), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea¿European Regional Development Fund. This work was funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (projects P18/01066, PI19/00175, PI21/00153, PI22/00433) and by ISCIII Programa Fortalece del Ministerio de Ciencia e Innovación (FORT23/00026); by CIBERNED (CIBER de Enfermedades Neurodegenerativas, project PI2020/08-1); by the Department of Education of the Basque Country through the IKUR strategy (NEURODEGENPROT); Diputación Foral de Gipuzkoa (projects 2020-CIEN-000057-01, 2021-CIEN-000020¿01); by EiTB Maratoia (project BIO17/ND/023/BD); and by Osasun Saila, Eusko Jaurlaritzako (projects 2015111122, 2017222027, 2018111042, 2019222020, 2020111032, 2020333043, 2021333050). MZuf, OP-M, MG-A, AJ, AE, JO, LR-G, and UF-P were supported by the Department of Education of the Basque Country (PhD fellowships PRE_2015_1_0023, PRE_2019_1_0339, PRE_2020_1_0122, PRE_2020_1_0191, PRE_2020_1_0119, PRE_2018_1_0095, PRE_2021_1_0125, PRE_2018_1_0253); MM-O by Basque Country University (UPV/EHU) fellowship (PIF18/317); JMG-V and VH-P were supported by the Valencian Council for Education, Culture, University and Employment (PROMETEO/2023/053); LB by the Spanish National Plan for Scientifc and Technical Research and Innovation -Ramon y Cajal- (RYC2018-024397-I) and IKERBASQUE (RF/2019/001) research programs; GG by Juan de la Cierva-Incorporación (ISCIII, IJC2019-039965-I) and IKERBASQUE (RF/2023/010) research programs; FG-B by Roche Stop Fuga de cerebros(BIO19/ROCHE/017/BD) and IKERBASQUE (PP/2022/003) research programs; and SA-M by Gipuzkoa Fellow of Talent Attraction and Retention (2019-FELL-000010-01, 2020-FELL-000016-02-01, and 2021-FELL-000013-02-01).